Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

Autor: Kf, Bol, Carl Figdor, Eh, Aarntzen, Me, Welzen, Mm, Rossum, Wa, Blokx, Mw, Rakt, Nm, Scharenborg, Aj, Boer, Jm, Pots, Ma, Olde Nordkamp, Tg, Oorschot, Rd, Mus, Sa, Croockewit, Jf, Jacobs, Schuler G, Neyns B, Jm, Austyn, Cj, Punt, Schreibelt G

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::05a9637520e2ca02c2362a62cc3829f5
http://europepmc.org/abstract/med/26405571

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.

Autor: Bol KF; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Schreibelt G; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Bloemendal M; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., van Willigen WW; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Hins-de Bree S; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., de Goede AL; Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands., de Boer AJ; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Bos KJH; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Duiveman-de Boer T; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Olde Nordkamp MAM; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., van Oorschot TGM; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Popelier CJ; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Pots JM; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Scharenborg NM; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., van de Rakt MWMM; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., de Ruiter V; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., van Meeteren WS; Department of Dermatology, Radboud university medical center, Nijmegen, The Netherlands., van Rossum MM; Department of Dermatology, Radboud university medical center, Nijmegen, The Netherlands., Croockewit SJ; Department of Hematology, Radboud university medical center, Nijmegen, The Netherlands., Koeneman BJ; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Creemers JHA; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Wortel IMN; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.; Department of Data Science, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands., Angerer C; Miltenyi Biotec, Bergisch Gladbach, Germany., Brüning M; Miltenyi Biotec, Bergisch Gladbach, Germany., Petry K; Miltenyi Biotec, Bergisch Gladbach, Germany., Dzionek A; Miltenyi Biotec, Bergisch Gladbach, Germany., van der Veldt AA; Departments of Medical Oncology and Radiology & Nuclear Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., van Grünhagen DJ; Department Surgical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Werner JEM; Department Surgical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Bonenkamp JJ; Department Surgical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Boers-Sonderen MJ; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Koornstra RHT; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Boomsma MF; Department of Radiology, Isala Oncology Center, Zwolle, The Netherlands., Aarntzen EHJ; Department of Medical Imaging, Radboud university medical center, Nijmegen, The Netherlands., Gotthardt M; Department of Medical Imaging, Radboud university medical center, Nijmegen, The Netherlands., Nagarajah J; Department of Medical Imaging, Radboud university medical center, Nijmegen, The Netherlands., de Witte TJM; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., Figdor CG; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands., de Wilt JHW; Department Surgical Oncology, Radboud university medical center, Nijmegen, The Netherlands., Textor J; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands.; Department of Data Science, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands., de Groot JWB; Department of Medical Oncology, Isala Oncology Center, Zwolle, The Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud university medical center, Nijmegen, The Netherlands., de Vries IJM; Medical Biosciences, Radboud Institute for Medical Innovation, Radboud university medical center, Nijmegen, The Netherlands. Jolanda.deVries@radboudumc.nl.

Publikováno v: Nature communications [Nat Commun] 2024 Feb 23; Vol. 15 (1), pp. 1632. Date of Electronic Publication: 2024 Feb 23.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

Autor: Boudewijns S; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Bol KF; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Schreibelt G; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., Westdorp H; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands., Textor JC; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., van Rossum MM; Department of Dermatology, Radboud University Medical Center , Nijmegen, the Netherlands., Scharenborg NM; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., de Boer AJ; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., van de Rakt MW; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., Pots JM; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., van Oorschot TG; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., Duiveman-de Boer T; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., Olde Nordkamp MA; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., van Meeteren WS; Department of Dermatology, Radboud University Medical Center , Nijmegen, the Netherlands., van der Graaf WT; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands; The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom., Bonenkamp JJ; Department of Surgical Oncology, Radboud University Medical Center , Nijmegen, the Netherlands., de Wilt JH; Department of Surgical Oncology, Radboud University Medical Center , Nijmegen, the Netherlands., Aarntzen EH; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands., Punt CJ; Department of Medical Oncology, Academic Medical Center , Amsterdam, the Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center Nijmegen , Nijmegen, the Netherlands., Figdor CG; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences , Nijmegen, the Netherlands., de Vries IJ; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands; Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands.

Publikováno v: Oncoimmunology [Oncoimmunology] 2016 May 31; Vol. 5 (7), pp. e1191732. Date of Electronic Publication: 2016 May 31 (Print Publication: 2016).

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Autor: Bol KF; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Aarntzen EH; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Pots JM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Olde Nordkamp MA; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., van de Rakt MW; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Scharenborg NM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., de Boer AJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., van Oorschot TG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Croockewit SA; Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands., Blokx WA; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands., Oyen WJ; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Boerman OC; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Mus RD; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., van Rossum MM; Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands., van der Graaf CA; Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands., Punt CJ; Department of Medical Oncology, Academic Medical Centre, Amsterdam, The Netherlands., Adema GJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Schreibelt G; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Gerty.Schreibelt@radboudumc.nl.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2016 Mar; Vol. 65 (3), pp. 327-39. Date of Electronic Publication: 2016 Feb 10.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Autor: Lesterhuis WJ; Department of Medical Oncology,Nijmegen Centre for Molecular Life Sciences, and Laboratory of Medical Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands., de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2011 Sep 01; Vol. 17 (17), pp. 5725-35. Date of Electronic Publication: 2011 Jul 19.